34.77 0.00 (0.00%)
After hours: 4:02PM EDT
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||34.51 - 34.86|
|52 Week Range||28.43 - 36.70|
|PE Ratio (TTM)||29.34|
|Forward Dividend & Yield||1.40 (4.05%)|
|1y Target Est||39.09|
Why Are Investors Excited about Nektar Therapeutics in 2018? Nektar Therapeutics (NKTR) generates revenues from collaboration agreements through which it receives product sales revenues, royalties, license fees, milestone payments, and contract research payments. In fiscal 2017, Nektar Therapeutics generated total revenues of $307.7 million compared with $165.4 million in fiscal 2016.
Amgen would be better off stringing together small deals, rather than attempting a megamerger, an analyst suggested Monday.
AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA® , in patients with type 2 diabetes with moderate renal impairment .
In March 2017, Merck (MRK) and Eisai entered into a collaboration to jointly develop and commercialize Lenvima, a TK (tyrosine kinase) inhibitor developed by Eisai. Merck and Eisai entered into the collaboration to jointly develop and commercialize Lenvima as monotherapy and in combination with Merck’s Keytruda. Lenvima is approved as a monotherapy for the treatment of thyroid cancer.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
By Brian Marckx, CFA NASDAQ:CEMI Chembio (NASDAQ:CEMI) reported Q4 2017 financial results and provided a business update. Despite declining on a sequential basis, both product sales and total revenue ...
AstraZeneca PLC (LSE:AZN) is trading with a trailing P/E of 28.2x, which is lower than the industry average of 32.9x. Although some investors may jump to the conclusion that thisRead More...
As discussed earlier, AstraZeneca surpassed Wall Street analyst estimates for earnings per share (or EPS) and revenues and reported EPS of $1.03 on revenues of ~$5.8 billion in 4Q17, a 3% increase in revenues as compared to revenues of 4Q16. AstraZeneca’s stock price has increased by nearly 14.9% over the last 12 months but decreased by ~2.6% in 2018 year-to-date. Wall Street analysts have a 12-month target price of $39.09 per share as compared to the last price of $33.78 per share as of March 8, 2018.
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
Key data on whether an AstraZeneca drug improves overall survival for those with non-small cell lung cancer that has spread elsewhere in the body will not now be released until the second half of the year, ...
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live with and without the company’s treatment.
LONDON (Reuters) - AstraZeneca (AZN.L) now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase ...
AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase III trial, known as Mystic, ...